FAKTOR-OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 15:45:56 2024-05-24 EDT | ||
| 1.14 EUR | -2.56% |
|
| Current month | -26.45% | ||
| 1 month | -23.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 1.14 | -2.56% |
| 24-05-23 | 1.17 | -1.68% |
| 24-05-22 | 1.19 | -2.46% |
| 24-05-21 | 1.22 | +2.52% |
| 24-05-20 | 1.19 | -0.83% |
Delayed Quote Deutsche Boerse AG
Last update May 24, 2024 at 03:45 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SF6H8G |
| ISIN | DE000SF6H8G2 |
| Date issued | 2021-11-11 |
| Strike | 191.1 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.1 € |
|---|---|
| Lowest since issue | 1.14 € |
| Spread | 0.01 € |
| Spread % | 0.87% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Certificates
- Certificat
